Who are Edwards Lifesciences's decision-makers?
Edwards Lifesciences is led by Bernard Zovighian. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Bernard Zovighian
- CFO/key exec
- Scott Ullem
- Founded
- 1958
- Employees
- 19,000+
- HQ
- Irvine, CA
- Status
- NYSE: EW
- Bernard ZovighianChief Executive OfficerCEO since 2023Leads Edwards as a focused structural-heart company.
- Scott UllemChief Financial OfficerCFO through planned 2026 transitionOversees finance and capital allocation.
- Larry WoodCorporate Vice President, Transcatheter Aortic Valve ReplacementBusiness-unit leaderLeads the core TAVR franchise.
- Daveen ChopraCorporate Vice President, Transcatheter Mitral and Tricuspid TherapiesBusiness-unit leaderLeads TMTT growth.
Who leads Edwards Lifesciences?
Edwards Lifesciences's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Edwards Lifesciences?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Edwards Lifesciences organized as it scales?
Edwards Lifesciences operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Edwards Lifesciences leadershipEdwards Lifesciences annual reports
Edwards Lifesciences — frequently asked questions
